Epidemiological, clinical, and genotypic characteristics of pediatric Mycoplasma pneumoniae infections: an 8-year survey in Suzhou, China in the pre- and post-COVID-19 eras.

Publication date: Aug 19, 2024

This study examines the epidemiology of Mycoplasma pneumoniae (M. pneumoniae) infections among children in Suzhou, China, during various pandemic phases. The goal is to discern evolving epidemic trends and to furnish robust evidence for clinical diagnosis and treatment. From January 1, 2016, to December 31, 2023, 113,625 consecutive patients with respiratory infections from three hospitals in Suzhou, China (Children’s Hospital of Soochow University, Children’s Hospital of Wujiang District, and Affiliated Suzhou Hospital of Nanjing University Medical School), were retrospectively enrolled in a surveillance study. Additionally, in 2023, children hospitalized with M. pneumoniae pneumonia at the Children’s Hospital of Soochow University were tested for genotype (P1 gene typing, SNP genotyping) and macrolide resistance in their bronchoalveolar lavage fluid. From 2016 to 2023, the M. pneumoniae positive detection rate among pediatric respiratory infections fell from a pre-pandemic 21. 1% to pandemic lows, then surged to 45. 3% post-pandemic. Before the pandemic, peak M. pneumoniae infection rates occurred in summer, followed by autumn. Post-pandemic, the highest peak rates were in autumn. Peak M. pneumoniae detection rates occurred in 2019 and 2023, with a notable increase in children aged 6 and older in 2023. In this study, 200 M. pneumoniae-positive bronchoalveolar lavage fluid (BALF) cases in 2023 were randomly selected and analyzed for P1 genotype and SNP genotype. Among 156 cases, 81. 4% were P1 genotype and 18. 6% were P2 genotype. The proportion of severe M. pneumoniae pneumonia with the P1 type was significantly higher than that with the P2 type (p

Open Access PDF

Concepts	Keywords
Genotyping	children
Nanjing	China
Pneumoniae	COVID-19
Typing	genotype
	Mycoplasma pneumoniae

Semantics

Type	Source	Name
disease	MESH	Mycoplasma pneumoniae infections
disease	MESH	COVID-19
disease	MESH	infections
disease	MESH	respiratory infections
disease	MESH	pneumonia
disease	IDO	infection
disease	MESH	mutation rates
drug	DRUGBANK	Coenzyme M
pathway	REACTOME	Reproduction
disease	MESH	infectious diseases
disease	MESH	complications
disease	IDO	country
disease	IDO	antibiotic resistance
disease	IDO	site
disease	MESH	tuberculosis
pathway	KEGG	Tuberculosis
disease	MESH	interstitial lung disease
disease	MESH	vasculitis
disease	IDO	nucleic acid
disease	IDO	bacteria
disease	MESH	restriction fragment length polymorphism
disease	IDO	assay
disease	MESH	dyspnea
drug	DRUGBANK	Oxygen
drug	DRUGBANK	Medical air
disease	MESH	bronchitis
disease	MESH	atelectasis
disease	IDO	pathogen
disease	IDO	susceptibility
pathway	REACTOME	Immune System
disease	MESH	influenza
disease	IDO	replication
disease	MESH	cross infection
disease	MESH	RSV infections
disease	MESH	clinical significance
disease	IDO	cell
drug	DRUGBANK	(S)-Des-Me-Ampa